Abstract
Background Cranial dural arteriovenous fistulas (dAVF) are rare complex vascular malformations that have a bleeding risk with potential lethal consequences. Despite this, knowledge of the vascular architectural features associated with the rupture risk are not always clearly defined.
Methods We retrospectively analyzed cranial arteriovenous fistulas in terms of their anatomical and angio-architectural features as evaluated on conventional subtraction angiography: Location of the fistula, fistula architecture, venous ectasia or pouches, presence of cortical draining veins, presence of pial feeders, outflow stenosis, presence of a major sinus thrombosis, flow-associated arterial aneurysms as well as presenting symptoms. Patterns in the data were identified after multiple components analysis followed by automatic k-means clustering and their predictive power was confirmed using a shallow feedforward neural network.
Results New relevant features predictive of hemorrhage, identified by using a shallow feed-forward neural network, were outflow stenosis, in addition to venous cortical drainage and venous ectasia. The neural network achieved relatively high performance metric, with area under the receiver operating characteristic curve (ROC AUC)) of 0.88 and accuracy of 0.8. We confirmed the relevance of these findings by performing a multiple correspondence analysis followed by k-means clustering in the angiographic feature vector space, additionally identifying architecture of the fistula as relevant factor. There was good agreement between the ground truth (hemorrhage) and the cluster labels (adjusted Rand score 0.273, purity index 0.82).
Conclusion Machine learning approach confirmed the importance of previously described features (cortical drainage and venous ectasia) but also uncovered novel relevant characters (outflow stenosis and fistula architecture) for the hemorrhage risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the University Witten-Herdecke gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
